Sparsentan therapy was associated with sustained decline in proteinuria and lower likelihood of progression to kidney failure ...

October 2025 saw a wave of M&As and biotech deals in various therapeutic fields, particularly for therapies addressing ...

In FSGS, podocytes are damaged, like a net with torn holes, allowing protein to leak into the urine, creating a harmful ...

The benefits are observed across patient subtypes and potentially offer the chance to avoid dialysis and implement a new standard of care.

Re-Time Pty Ltd (RTPL) today announced the launch of the retimer Ring, the first smart ring solution developed by an Australian company to help people improve sleep and overall wellbeing. Building on ...

Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced new data from the Phase 3 DUPLEX Study demonstrating that patients with focal segmental glomerulosclerosis (FSGS) treated with FILSPARI® ...

Information Services Group (ISG) , a global AI-centered technology research and advisory firm, has launched a research study examining providers in the ServiceNow ecosystem that are helping ...

Ligand is increasing its 2025 full year financial guidance. The Company now expects total core revenue of $225 million to ...

Fintel reports that on November 4, 2025, Piper Sandler maintained coverage of Travere Therapeutics (NasdaqGM:TVTX) with a ...

Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that company management will participate in the following upcoming investor conferences: Presenting on Tuesday, November 11, 2025, at 9:00 a.m ...

Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Travere Therapeutics, Inc. recently held its earnings call, revealing a strong quarter ...

We recently published 10 Firms Dominating the Market; 5 at All-Time Highs. Travere Therapeutics, Inc. (NASDAQ:TVTX) is one of ...